A Randomized, Open Label, Single Dose, 2-way Crossover Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers
Latest Information Update: 05 Apr 2021
At a glance
- Drugs HIP 2001 (Primary)
- Indications Atrial fibrillation
- Focus Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
- 30 Mar 2021 Status changed from active, no longer recruiting to completed.
- 25 Feb 2021 New trial record